In other words, multiple factors must be considered in managing EGFR-mutant NSCLC, including the limitations of EGFR-TKI monotherapy, the co-occurrence of other genetic alterations, and the prognostic implication of high PLK1 expression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.